Navigation Links
WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
Date:7/22/2009

SHANGHAI, July 23 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Chi-Chung Chan has been appointed as Vice President of Pharmacology. He will report directly to Dr. Shuhui Chen, Chief Scientific Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi, Dr. Chi-Chung Chan worked at Merck & Co. for 26 years in scientific positions of increasing responsibility. At Merck, he led pharmacology research efforts in inflammation and pain, allergic diseases, cardiovascular diseases, respiratory diseases and, most recently, diabetes and obesity. Dr. Chan obtained a Ph.D. in Pharmacology from the University of Ottawa and a B.S. degree in Biology from Chinese University of Hong Kong.

"I am pleased to welcome Chi-Chung on board as we continue to develop our drug discovery capabilities in pharmacology," said Dr. Ge Li, Chairman and Chief Executive Officer. "WuXi is committed to building a world-class scientific management team with extensive experience in a broad range of scientific disciplines to meet the needs of our customers."

    For more information, please contact:

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Stephanie Liu (for the media)
     Associate Director of Corporate Communications Department
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
6. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
7. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
10. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
11. WuXi PharmaTech 2007 Annual Report Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of Pennsylvania ... have made a $10 million gift to establish the Ken Moelis and Julie ... pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as ... they either don’t have access to a health care facility or a pharmacy within 60 ... of the United States or for many who are faced with health or personal issues ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading provider ... a free, public-facing tool for analyzing the costs of various drug regimens in ... information to patients, providers, insurers and pharmaceutical companies about the estimated costs of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology: